OS Therapies Inc 8-K

What Happened
OS Therapies Inc. (OSTX) announced it entered into a securities purchase agreement on March 31, 2026 and closed a registered direct offering on April 2, 2026. The Offering included 2,505,073 shares of common stock (and, in lieu of some shares, pre‑funded warrants) plus accompanying common warrants, with net proceeds to the company of approximately $4.7 million. The company said it will use the funds to support clinical development and R&D, pursue complementary acquisitions or investments, and for working capital and general corporate purposes.

Key Details

• Offering closed April 2, 2026; combined purchase price per share (with accompanying common warrant) was $1.40; where a pre‑funded warrant was used the purchase price was $1.399.
• Securities issued: 2,505,073 common shares and pre‑funded warrants to purchase up to 1,250,893 shares, with accompanying common warrants to purchase up to 3,755,966 shares. Net proceeds ≈ $4.7M.
• Pre‑funded warrants: exercisable immediately, $0.001 exercise price, holder exercise caps (default 4.99% ownership; option for 9.99%; can be adjusted up to 19.99% with notice).
• Common warrants: immediately exercisable, $1.40 exercise price, 5‑year term. Neither pre‑funded nor common warrants are expected to be listed on an exchange.
• Placement agent: Ceros Financial Services acted as exclusive placement agent for a 7.0% cash fee, expense reimbursements (up to $70k accountable, $20k non‑accountable) and placement agent warrants for 187,798 shares at $1.54 per share (exercisable after 6 months, expire in 5 years).

Why It Matters
This financing extends OS Therapies’ cash runway to advance clinical programs and other corporate priorities, while creating potential future dilution through outstanding warrants (company warrants and placement agent warrants). Key investor considerations include the exercise prices and terms of the warrants, the ownership caps on exercises (which limit large single‑holder dilutions), and the short‑term lock‑up on issuing new securities (90‑day restriction, 180 days for certain variable‑rate transactions) disclosed in the purchase agreement.